209 related articles for article (PubMed ID: 24172733)
1. Serum phosphorus in people with chronic kidney disease: you are what you eat.
Tonelli M
Kidney Int; 2013 Nov; 84(5):871-3. PubMed ID: 24172733
[TBL] [Abstract][Full Text] [Related]
2. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
3. Phosphorus binders: The new and the old, and how to choose.
Sekar A; Kaur T; Nally JV; Rincon-Choles H; Jolly S; Nakhoul GN
Cleve Clin J Med; 2018 Aug; 85(8):629-638. PubMed ID: 30102593
[TBL] [Abstract][Full Text] [Related]
4. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
[TBL] [Abstract][Full Text] [Related]
7. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
[TBL] [Abstract][Full Text] [Related]
8. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Koiwa F; Terao A
Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
[TBL] [Abstract][Full Text] [Related]
9. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
[TBL] [Abstract][Full Text] [Related]
11. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
[TBL] [Abstract][Full Text] [Related]
12. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Floege J
Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
[TBL] [Abstract][Full Text] [Related]
13. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
14. Use of phosphate-binding agents is associated with a lower risk of mortality.
Cannata-Andía JB; Fernández-Martín JL; Locatelli F; London G; Gorriz JL; Floege J; Ketteler M; Ferreira A; Covic A; Rutkowski B; Memmos D; Bos WJ; Teplan V; Nagy J; Tielemans C; Verbeelen D; Goldsmith D; Kramar R; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Sánchez JE; Martínez-Camblor P; Naves-Díaz M; Carrero JJ; Zoccali C
Kidney Int; 2013 Nov; 84(5):998-1008. PubMed ID: 23823605
[TBL] [Abstract][Full Text] [Related]
15. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
16. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
17. [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].
Massy ZA; Maizel J
Nephrol Ther; 2014 Nov; 10(6):441-50. PubMed ID: 25070605
[TBL] [Abstract][Full Text] [Related]
18. Educating your patient helps to control serum phosphate and also save 200 euros per patient.
Rodriguez-Palomares JR; Japaz Cancino MC; Blazquez Collado L; Fiallos Criollo R; Villabon Ochoa PM; Sanchez Heras M; Basterrechea MA; de Arriba de la Fuente G
Nefrologia; 2017; 37(1):103-105. PubMed ID: 27825657
[No Abstract] [Full Text] [Related]
19. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Greig SL; Plosker GL
Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
[TBL] [Abstract][Full Text] [Related]
20. Phosphate management in chronic kidney disease.
Bhan I
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]